New prostate cancer urine test shows how aggressive disease is and could reduce invasive biopsies
Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is.
A new study published today shows how an experimental new test called ExoGrail has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.
The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent.
Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man s lifetime.
E-Mail
April 26, 2021 - Wolters Kluwer, Health announced today the addition of two fully open access journals to the Lippincott® portfolio as part of a shared mission with Shandong University to expand the reach of healthcare discoveries globally with the publication of
Emergency and Critical Care Medicine and
Current Urology. The new open access titles publish original research in their respective medical specialties. We are always looking to increase access to quality scientific research and the addition of these open access journals to our portfolio supports that mission, said Jennifer Brogan, Vice President, Journal Publishing & Society Services at Wolters Kluwer, Health Learning, Research & Practice. We are delighted to build upon our relationship with Shandong University with these titles and to help them deliver impactful clinical research to healthcare professionals worldwide.
E-Mail
Credit: Professor Hirofumi Kai
Researchers from Kumamoto University (Japan) have found that the anti-diabetic drug metformin significantly prolongs the survival of mice in a model that simulates the pathology of non-diabetic chronic kidney disease (ND-CKD) by ameliorating pathological conditions like reduced kidney function, glomerular damage, inflammation and fibrosis. Metformin s mechanism is different from existing therapeutics which only treat symptoms, such as the blood pressure drug losartan, so the researchers believe that a combination of these medications at low dose will be highly beneficial.
CKD (chronic kidney disease) is a general term for kidney damage that results from persistent decline in kidney function due to proteinuria, kidney inflammation, or fibrosis. As CKD progresses, patients are forced to undergo dialysis, and diabetes is one of its biggest risk factors. CKD can also occur in association with lifestyle-related conditions such as hypertension, in
E-Mail
CLEVELAND, Ohio (March 17, 2021) As women age, they are more likely to wake up in the middle of the night to pass urine. The loss of estrogen during the menopause transition accelerates this problem, which is known as nocturia. A new study evaluated the effectiveness of different hormone therapies in managing the frequency of nocturia. Study results are published online today in
Menopause, the journal of The North American Menopause Society (NAMS).
The loss of estrogen during menopause has been shown to create bladder dysfunction, sleep disorders, hot flashes, and alterations in renal water and salt handling, all of which result in higher diuresis overnight. To date, there has been little research done regarding the effect of hormone therapy on nocturia, even though hormone therapy has been proven to improve the causative factors of postmenopausal nocturia such as sleep disorders, obstructive sleep apnea, and hot flashes.
Findings of this study suggest that patients recovering from COVID-19-associated acute kidney injury require monitoring of kidney function following hospital discharge.